Costs of SGLT2 inhibitors and GLP-1 receptor agonists need to be lowered substantially to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.
Background
The present study was conducted to assess the renal effects of high dose versus low dose lisinopril in patients with diabetic nephropathy.
Methodology
A prospective observational study was conducted at the Khyber Teaching Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan, between July 1, 2019, to January 1, 2020. Patients were divided into two groups. Group A patients were administered a low dose (5 mg per day) of Lisinopril and group B were administered a higher dose of therapy (20 mg/day) for three months. At the end of the study, baseline renal functions, electrolytes, and status of microalbuminuria were compared with follow-up values. The primary outcome was to assess the change in microalbuminuria levels in patients at baseline, one month, and three months of therapy.
Results
A total of 72 patients were included in group A (low dose) and 72 patients were enrolled in group B (high dose). The mean ages of group A and group B were 56.3 ± 12.9 years and 53.48
New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure will be presented at the first in-person EASD meeting for 3 years.